Dr. Lincoln Nadauld helped to develop technologies at Stanford University that identify DNA changes in cancer to predict whether or not a targeted cancer drug might be effective for a specific patient. Dr. Nadauld is one of a limited number of physicians who specialize in cancer genomic medicine.
“We are thrilled to have Dr. Nadauld lead our cancer genomic medicine program,” said Gary Stone, operations officer for Intermountain’s cancer programs in southwestern Utah. “Basing the program at Dixie Regional is especially exciting. Dr. Nadauld wants to come here to found and build this program for Intermountain, and to raise his family in one of the most beautiful settings in the world."
Stone explained that Dr. Nadauld’s work is a major stride forward in helping those who are diagnosed with cancer choose the most effective treatment. “Most importantly, genetic sequencing has the potential to offer targeted treatment options for patients with difficult-to-treat cancers, or for whom few options remain,” he said. “It also helps us utilize resources wisely."
Originally from Utah, Dr. Nadauld attended Brigham Young University for his undergraduate degree and went on to complete medical and doctoral degrees (MD/PhD) followed by internship and residency at the University of Utah. His doctoral dissertation focused on the molecular genetics of colon cancer. He completed a fellowship in medical oncology at Stanford University where he remained as faculty at the Stanford School of Medicine focusing on cancer genomics and personalized cancer medicine. Last year Dr. Nadauld was awarded the prestigious Young Investigator Award by the American Society of Clinical Oncology and the Career Development Award of the National Cancer Institute.